FDA Panel Weighs Safety Issues Of Endo Opioid Painkiller
A U.S. Food and Drug Administration advisory committee is mulling whether the risks of Endo Pharmaceutical's opioid painkiller Opana ER outweigh its benefits, discussing in meetings Monday and Tuesday whether the...To view the full article, register now.
Already a subscriber? Click here to view full article